← Back to patent-cliff list
琥珀酸索利那新
Tier C — Watch / tradeSolifenacin Succinate
安斯泰来制药集团
Originator
2004
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：CHRM3
Brand：Vesikur、卫喜康、Vesicare OD、Vesicare
Indications (approved)：膀胱过度活动症
Regional status
US
撤市
EU
终止
2003-07-01
China
批准上市
2009-05-22
Japan
批准上市
2006-04-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Solifenacin Succinate?
Approved indications include: 膀胱过度活动症.
When does the Solifenacin Succinate patent expire?
No public expiry year is available for Solifenacin Succinate yet; this page updates once verified.
How do I get a quote for Solifenacin Succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25